Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CHS-1000 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Single Agent CHS-1000 | EXPERIMENTAL | - |
| Part B: Combination Agents CHS-1000 + Toripalimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CHS-1000 | BIOLOGICAL | Specified dose on specified days |
| Toripalimab | BIOLOGICAL | Specified dose on specified days |
Key Inclusion Criteria: * Histopathologically or cytologically confirmed diagnosis of advanced or metastatic unresectable solid tumors (excluding glioblastoma multiforme (GBM)) by tissue biopsy or archival tumor specimen. Unresectable tumors are defined as tumors with lesions in which clear surgica...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CHS-1000 is an investigational monoclonal antibody being developed for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with advanced or metastatic solid tumors.
CHS-1000 targets ILT4, also known as LILRB2, a protein involved in immune regulation. By targeting ILT4, the antibody is designed to modulate the immune response against tumors. This mechanism is being evaluated in the context of advanced or metastatic solid tumors.
CHS-1000 is being developed by Coherus Oncology, Inc., a subsidiary of Coherus BioSciences, which trades under the ticker CHRS on the NASDAQ. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of CHS-1000 in patients with advanced or metastatic solid tumors.
CHS-1000 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by the FDA. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of CHS-1000 in patients with advanced or metastatic solid tumors.
CHS-1000 is being studied in a Phase 1 clinical trial with the identifier NCT06389526. This trial is titled 'A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors' and is not yet recruiting. The study plans to enroll 48 participants aged 18 years and older.
CHS-1000 is a distinct investigational monoclonal antibody and is not known to be the same as any other drug. It is being developed specifically for the treatment of advanced or metastatic solid tumors and is currently in Phase 1 clinical trials.